Enflonsia
Payments companies reported to CMS as associated with Enflonsia. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Enflonsia, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Enflonsia
These are the largest totals companies reported as associated with Enflonsia. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Octavio Ramilo | Memphis, TN | Pediatric Infectious Diseases | $38,408.16 |
| Christopher Belcher | Carmel, IN | Pediatric Infectious Diseases | $34,141.99 |
| Laura Scalfano | Plano, TX | Pediatrics | $24,456.51 |
| Flor De Maria Munoz | Houston, TX | Pediatric Infectious Diseases | $22,920.46 |
| Marcus Degraw | Detroit, MI | Pediatrics | $17,110.02 |
| Todd Wolynn | Pittsburgh, PA | Pediatrics | $16,186.81 |
| Jaime Fergie | Corpus Christi, TX | Pediatric Infectious Diseases | $12,123.38 |
| Kathryn Edwards | Nashville, TN | Pediatric Infectious Diseases | $3,487.50 |
| Roy Chemaly | Houston, TX | Infectious Disease | $3,480.00 |
| Joseph Domachowske | Syracuse, NY | Pediatric Infectious Diseases | $3,480.00 |
Prescribed Enflonsia?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.